COVID-19 press releases

COVID-19 press releases

After assessing safety and immunogenicity in phase 1/2 clinical trials, NVX-CoV2373 is currently in two pivotal phase 3 studies to evaluate vaccine efficacy, safety and immunogenicity. 

NVX-CoV2373 clinical trials have enrolled more than 30,000 volunteers around the globe. Learn more about our clinical trial enrollment and progress toward diversity demographics.


Visit our global authorization website

Our commitment to equitable access and transparency

Announcement of UK and South Africa trial results

Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial

PREVENT-19 fact sheet

Background information on PREVENT-19, Novavax pivotal phase 3 trial

Showper page